NCT05365893View on ClinicalTrials.gov

PHL Treatment in Pancreatic Cancer

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 20, 2021

Primary Completion Date

March 31, 2026

Study Completion Date

December 31, 2026

Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
COMBINATION_PRODUCT

Paricalcitol, Hydroxychloroquine, Losartan

Paricalcitol 25 mcg IV administered M-W-F Hydroxychloroquine 600 mg PO BID Losartan 50 mg PO daily

OTHER

Neoadjuvant therapy and surgery only (Control)

Control arm These patients will proceed to surgery at completion of neoadjuvant therapy.

Trial Locations (1)

19111

RECRUITING

Fox Chase Cancer Center, Philadelphia

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fox Chase Cancer Center

OTHER